Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 30, 2016
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - April 30, 2016

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/30/16 - AbbVie, Biogen gain CHMP nod for new MS drug Zinbryta [Ventures Africa]
AbbVie and partner Biogen are just months away from a European approval for their new multiple sclerosis mAb after the CHMP gave the drug a green light today. This is based on results from two clinical trials, Decide and Select, in which the drug, when injected every four weeks, improved results on key measures of MS disease activity in patients wi
4/30/16 - Acorda Therapeutics Announces Preliminary Tender Offer Results and Acceptance of the Shares, American Depositary Shares, Stock Options, Share Units...
Acorda Therapeutics Announces Preliminary Tender Offer Results and Acceptance of the Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies Corp. Tendered in Tender Offer. By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week On 11 March 2016, Acorda Therapeutics, Inc. commenced a volunta
4/30/16 - AG Recovers Record $46.7 Million for the State Medicaid Program from Pharma Co. WyethS Underpayments [National Iraqi News Agency (Iraq)]
Attorney General Bob Ferguson today announced the recovery of millions in overcharges to Washington by Wyeth, a pharmaceutical company owned by Pfizer, Inc. The agreement in principle resolves allegations the company knowingly underpaid rebates owed to Medicaid. After accounting for the federal governments Medicaid program share, Washington will...
4/30/16 - Attorney Joe Garza: Attacks on Corporations May Hurt American Citizens
By a News Reporter-Staff News Editor at Marketing Weekly News The U.S. Treasury Department took another well-aimed blow at the pharmaceutical industry on Monday night when it announced significant measures to curb the use of "tax inversions." But making things harder on U.S. corporations doesn't help ordinary citizens all that much. "U.S. corpor
4/30/16 - CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI enzalutamide
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Astellas Pharma Inc. and Medivation, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending approval of a type II variation to include data from the head-to-head TERRAIN trial of enzal
4/30/16 - Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors
By a News Reporter-Staff News Editor at Marketing Weekly News Cipher Pharmaceuticals Inc. announced that Rosemary A. Crane and Dr. Previously, Ms. Crane served as President and Chief Executive Officer of MELA Sciences, Inc. from 2013 to 2014. Ms. Crane was Head of Commercialization and a partner at Appletree Partners from 2011 to 2013. Ms. Crane
4/30/16 - DRAP to further drag pricing issue [Pakistan Observer]
The drug pricing policy was finalized and approved in march 2015, and the DRAP had already increased the drug prices after a long period of 10 years by only 1.5% per annum on November 27, 2013 to provide interim relief to the ailing pharma industry. It has been learnt that SHC has categorically directed DRAP and Ministry for providing minutes of la
4/30/16 - ESSENTIAL DRUG AVAILABILITY, PRICING POLICY TO BE REVISITED [Pakistan Observer]
Ministry of National Health Services, Regulations Coordination and Pharmaceutical Manufacturers have agreed in principle to revisit the Essential Drug Availability and Pricing Policy. Fauji Foundation University Medical College, Islamabad and Dr. Inam ul Haq, Former Drugs Controller and Chairman Quality Control Authority and Dean and Director, Riph
4/30/16 - Gilbane Breaks Ground on Biopharmaceutical Manufacturing Facility in Norton, Massachusetts [Khaleej Times (United Arab Emirates)]
-State and Community officials, including Charlie Baker, the Governor of Massachusetts; Kimberly Haugstad, Executive Director of the Hemophilia Federation of America; Travis McCready, President and Chief Executive Officer of the Massachusetts Life Sciences Center and Lisa Nelson, Senior District Representative to U.S. Congressman Joseph Kennedy III
4/30/16 - Immunomedics Reports Responses With Sacituzumab Govitecan (IMMU-132) in Patients With Metastatic Solid Cancers Who Failed Prior Checkpoint-Inhibitor... [Palestine Chronicle, The]
-Immunomedics, Inc. today announced that objective durable responses have been achieved with sacituzumab govitecan, its lead antibody-drug conjugate, in a number of patients with advanced, metastatic solid cancers, after failing multiple prior therapies, some including checkpoint inhibitors. The ADC has previously been granted Breakthrough Therapy.
4/30/16 - India : AUROBINDO PHARMA gets terminal USFDA affirmation for Esomeprazole Magnesium Delayed-release Capsules [TendersInfo (India)]
Aurobindo Pharma Limited has gained last sanctioning from the US Food& Drug Administration to manufacture and market Esomeprazole Magnesium Delayed-release Capsules USP, 20 mg and 40 mg. The launch of this item is depended on the settlement terms/ litigation results with AstraZeneca. The sanctioned ANDA is bioequivalent and therapeutically equivale
4/30/16 - Indiana to receive $9.2M share from Medicaid settlement [Arab News (Saudi Arabia)]
The federal government and 34 other states will share in the $784.6 million settlement from Wyeth, a subsidiary of Pfizer Inc., for not charging state Medicaid programs the best price available for two proton-pump inhibitors, used to treat peptic ulcers and acid reflux disease. Under the federal Medicaid Prescription Drug Rebate Program, pharmaceut
4/30/16 - Japan : Phase 3 Trial results for First Oral Proteasome Inhibitor NINLARO (ixazomib) published in The New England Journal of Medicine [TendersInfo (India)]
Takeda Pharmaceutical Company Limited today announced that results from the international, randomized, double-blind, placebo-controlled TOURMALINE-MM1 Phase 3 clinical study, evaluating once-weekly oral NINLARO capsules plus lenalidomide and dexamethasone versus placebo plus lenalidomide-dexamethasone in patients with relapsed and/or...
4/30/16 - SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Horizon Pharma plc of Class Action Lawsuit and Upcoming... [National Iraqi News Agency (Iraq)]
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Horizon Pharma plc of Class Action Lawsuit and Upcoming Deadline HZNP. -Pomerantz LLP announces that a class action lawsuit has been filed against Horizon Pharma plc and certain of its officers. The class action, filed in United States District Court, Sout
4/30/16 - Today, a New Drug Takes Approximately 15 Years and Over $1 Billion to Bring to Market - Research and Markets
By a News Reporter-Staff News Editor at Investment Weekly News Research and Markets has announced the addition of the "Vital Signs- Lowering Drug Development Costs with Genetically Modified Swine" report to their offering. The US pharmaceutical industry spends approximately $100 billion annually to develop new pharmaceutical drugs and medical dev
4/29/16 - "Solid Pharmaceutical Dosage Form for Release of at Least One Active Pharmaceutical Ingredient in the Oral Cavity" in Patent Application Approval...
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Hugerth, Andreas; Lindell, Katarina; Nicklasson, Fredrik; Thyresson, Kristina, filed on June 2, 2014, was made available online on April 14, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application
4/29/16 - AbbVie Announces Real-World Data with VIEKIRAX ombitasvir/paritaprevir/ritonavir tablets and EXVIERA dasabuvir tablets from Large German Hepatitis...
By a News Reporter-Staff News Editor at Drug Week AbbVie, a global biopharmaceutical company, announced new real-world data showing 96 percent of genotype 1 patients and 100 percent of genotype 4 patients achieved sustained virologic response at 12 weeks post-treatment. "Real-world studies complement randomized controlled trials and help to furt
4/29/16 - AbbVie buys cancer drug firm for $5.8 billion [Chicago Tribune]
AbbVie CEO Richard Gonzalez told investors on an earnings call Thursday morning that the incentives are critical to ensure AbbVie can retain Stemcentrx staff who have five experimental drugs in human trials, including a drug called Rova-T, which could be on the market as soon as 2018.. If approved, the cancer drugs would help AbbVie cope with growi
4/29/16 - AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous...
AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals. By a News Reporter-Staff News Editor at Drug Week AbbVie, a global biopharmaceutical company, announced that 91 percent of genotype 1 chronic hepatitis C virus in
4/29/16 - ABLYNX ANNOUNCES MILESTONE IN DRUG DISCOVERY COLLABORATION
Dr Edwin Moses, CEO of Ablynx, commented: "We are very pleased that Novartis will soon begin clinical development of this novel Nanobody against a GPCR. About the collaboration between Novartis and Ablynx. In December 2005, Ablynx and Novartis entered into an agreement to discover and develop novel Nanobody-based therapeutics against a number of di
4/29/16 - Advanced Accelerator Applications reports 26.8% sales growth in 2015 and continues to show significant clinical progress across both therapeutic and diagnostic platforms
Stefano Buono, AAA s CEO, commented, 2015 was a pivotal year for AAA. We also submitted an NDA and MAA in the U.S. and Europe, respectively, for Somakit, which could be the ideal in-vivo companion diagnostic for Lutathera.. With our Lutathera filing now complete and submitted to the FDA and the EMA and the anticipated Somakit approval in b
4/29/16 - Allergan Acquires Topokine Therapeutics to Focus on Topical Medicines for Undereye Fat Reduction
Allergan, a global pharmaceutical company, acquired Topokine Therapeutics, developer of XAF5 topical element for steatoblepharon, or bags under the eyes.
4/29/16 - Allergan Receives CHMP Positive Opinion For ENZEPI (Pancrelipase) For Patients With Exocrine Pancreatic Insufficiency (EPI)
Allergan plc, a leading global pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use has adopted a Positive Opinion for the Marketing Authorisation of ENZEPI in the European Union. 1 ENZEPI is a pancreatic enzyme replacement therapy for patients with exocrine pancreatic insufficiency due to cystic f
4/29/16 - Allergan Reinforces Commitment to Anti-Infective Innovation with 20 Abstracts Highlighted at ECCMID 2016
By a News Reporter-Staff News Editor at Drug Week Allergan plc, a leading global pharmaceutical company committed to developing new treatment options for infectious diseases, announced that new data from its anti-infective portfolio will be featured in 20 abstracts during the upcoming European Congress of Clinical Microbiology and Infectious...
4/29/16 - An Application for the Trademark "SHARE SOLUTIONS SUPPORT. KNOWLEDGE. ANSWERS." Has Been Filed by Teva Pharmaceuticals USA
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "SHARE SOLUTIONS SUPPORT. by Herschel Perel, representing Teva Pharmaceuticals USA. This application was made available to the public on April 08, 2016.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415